

09-03-2010

Orphazyme announces the completion of its seed financing with Novo Seeds joining as investor.

Orphazyme develops pharmaceuticals that target lysosomes. The company is dedicated to developing a novel class of therapeutics for the treatment of lysosomal storage diseases, a family of rare but debilitating disorders. Orphazyme is built on the discoveries of its scientific founders Thomas Kirkegaard Jensen and Marja Jäättela, some of which were published earlier this year in Nature.

The financing will allow the company to reach proof-of-concept for its lead clinical candidate, and support the expansion of the pipeline as well as strengthening the IP position.

Adjunct to the financing Anders Hinsby will take the position as CEO of Orphazyme: " *I am excited that Novo Seeds has decided to join as investor. Orphazyme has a very strong scientific and IP foundation due to the pioneering work of our scientific founders. The Novo Seeds investment provides us with optimal conditions for gaining momentum in developing a novel class of therapeutics for lysosomal diseases*"

Henrijette Richter, Investment Director and Bobby Soni, Associate will be joining the board of Orphazyme in connection with the seed investment. They state " *We have been impressed with the results Orphazyme has generated with a pre-seed grant from Novo Seeds, and we are pleased to follow this with a seed investment. Orphazyme clearly fits our investment strategy of investing in early stage Scandinavian life sciences companies based on outstanding science*".

For more information about Orphazyme:

Anders Hinsby, CEO: e-mail: amh@orphazyme.com, tel: +45 28989056

For more information about Novo Seeds:

Henrijette Richter, Investment Director: e-mail: heri@novo.dk

Bobby Soni, Associate: e-mail: bygs@novo.dk

About lysosomal storage diseases

Lysosomal storage diseases are a group of approximately 40 rare genetic [disorders](#) that result from deficiencies of lysosomal enzymes or other lysosomal components, and can result in accumulation of undegraded metabolites. Examples of lysosomal storage diseases include Gaucher's disease, Fabry's disease and Niemann-Pick disease. The symptoms and severity of lysosomal storage disease vary, but affect mostly children and they often die at a young age. Diagnosed incidences of individual lysosomal storage diseases are generally less than 1 in a 100.000 births, but combined the incidence rate is 1:5.000-1:10.000.

About the Investor

Novo A/S and Novo Seeds:

Novo A/S is the holding and investment company of the Novo Group, and is wholly owned by the Novo Nordisk Foundation. Novo A/S was formed in 1999 to actively manage the assets of the foundation. It employs about 30 people and has approximately USD 15 billion of assets under management. These includes significant shareholdings in the publicly listed Novo Nordisk A/S